{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:14:52Z","timestamp":1792790092225,"version":"4.5.0"},"reference-count":50,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Inc. (United States)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Respiratory syncytial virus (RSV) is the leading cause of severe respiratory disease in infants worldwide. Maternal immunization to protect younger infants is supported by evidence that virus-neutralizing antibodies, which are efficiently transferred across the placenta from mother to fetus, are a primary immune mediator of protection. In maternal RSV vaccine studies, estimates of correlates of protection are elusive because many factors of maternal\u2013fetal immunobiology and disease characteristics must be considered for the estimates. Methods: We developed statistical models that aims to predict vaccine efficacy (VE) in infants following maternal immunization by including quantifiable covariates of the antibody titer distribution of the mother (pre- and post-immunization), the transplacental transfer ratio of IgG antibodies, the rate of antibody decay, and RSV disease incidence rate, all of which are season- and time-dependent and vary by infant age. Result: Our model shows that integrating the lower respiratory tract disease risk based on infant airway diameter and associated airway resistance is critical to appropriately model predicted infant VE. The VE predictions by our models, which preceded maternal RSV prefusion F vaccine efficacy trial primary readouts, closely align with the VE outcomes of these field studies. Conclusion: Our models successfully predicted VE of the RSV maternal vaccines and have potential use in modeling the clinical trial out-comes of other respiratory disease vaccines where maternal antibodies play a role in the protection of newborns.<\/jats:p>","DOI":"10.3390\/vaccines12121351","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T02:57:08Z","timestamp":1732849028000},"page":"1351","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization"],"prefix":"10.3390","volume":"12","author":[{"given":"Bing","family":"Cai","sequence":"first","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc., Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Development and Operations, Pfizer Inc., Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Agosti","sequence":"additional","affiliation":[{"name":"Chief Medical Affairs Office, Pfizer Inc., Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Schmoele-Thoma","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Koury","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Gruber","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Dormitzer","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-8414","authenticated-orcid":false,"given":"Kena A.","family":"Swanson","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc., Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Murray, J., Bottle, A., Sharland, M., Modi, N., Aylin, P., Majeed, A., Saxena, S., and Medicines for Neonates Investigator Group (2014). Risk factors for hospital admission with RSV bronchiolitis in England: A population-based birth cohort study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089186"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/jp.2016.113","article-title":"Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants","volume":"36","author":"McLaurin","year":"2016","journal-title":"J. Perinatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/infdis\/jiaa046","article-title":"Respiratory Failure and Death in Vulnerable Premature Children with Lower Respiratory Tract Illness","volume":"222","author":"Ofman","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Boyoglu-Barnum, S., Chirkova, T., and Anderson, L.J. (2019). Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01675"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/infdis\/jiu316","article-title":"Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh","volume":"210","author":"Chu","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.12.2.298","article-title":"Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment","volume":"12","author":"Domachowske","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_9","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am. J. Dis. Child."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/INF.0000000000001533","article-title":"Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis","volume":"36","author":"Anderson","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1080\/21645515.2020.1843336","article-title":"Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children","volume":"17","author":"Viguria","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants","volume":"102","author":"Group","year":"1998","journal-title":"Pediatrics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J. Pediatr."},{"key":"ref_16","unstructured":"Payne, A. (2024, June 30). Summary of Effectiveness of Nirsevimab in Infants, Available online: https:\/\/stacks.cdc.gov\/pdfjs\/web\/viewer.html?file=https:\/\/stacks.cdc.gov\/view\/cdc\/157872\/cdc_157872_DS1.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_18","unstructured":"FDA (2023, September 26). FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants."},{"key":"ref_19","unstructured":"EMA (2024, March 12). First RSV Vaccine to Protect Infants up to 6 Months of Age and Older Adults. Available online: https:\/\/www.ema.europa.eu\/en\/news\/first-rsv-vaccine-protect-infants-6-months-age-and-older-adults."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"eade6422","DOI":"10.1126\/scitranslmed.ade6422","article-title":"Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine","volume":"15","author":"Che","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_21","first-page":"197","article-title":"A Statistical Model of RSV Disease in Neonates and Efficacy Prediction for Maternal","volume":"27","author":"Cai","year":"2019","journal-title":"Vaccines"},{"key":"ref_22","unstructured":"Novavax (2024, November 25). Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax\u2122 for Prevention of RSV Disease in Infants via Maternal Immunization. Available online: https:\/\/ir.novavax.com\/press-releases\/2019-02-28-Novavax-Announces-Topline-Results-from-Phase-3-PrepareTM-Trial-of-ResVax-TM-for-Prevention-of-RSV-Disease-in-Infants-via-Maternal-Immunization."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S982","DOI":"10.1093\/ofid\/ofz360.2458","article-title":"Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers","volume":"6","author":"Cai","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy","volume":"386","author":"Simoes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.virusres.2004.02.024","article-title":"Seroprotection rate, mean fold increase, seroconversion rate: Which parameter adequately expresses seroresponse to influenza vaccination?","volume":"103","author":"Beyer","year":"2004","journal-title":"Virus Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/infdis\/jiab612","article-title":"A Randomized Phase 1\/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine","volume":"225","author":"Walsh","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1164\/ajrccm\/140.6.1717","article-title":"Airway size and structure in the normal fetal and infant lung and the effect of premature delivery and artificial ventilation","volume":"140","author":"Hislop","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_29","first-page":"76","article-title":"Sur le mouvement des liquides de nature differente dans les tubes de tres petits diametres","volume":"3","author":"Poiseulle","year":"1847","journal-title":"Ann. Chim. Phys."},{"key":"ref_30","unstructured":"Madhi, S.A., Simoes, E.A., Klein, N.P., Zareba, A., Dormitzer, P.R., Scott, D.A., Gurtman, A., Gruber, W.C., Jansen, K.U., and Cooper, D. (2024). Dynamics of Respiratory Syncytial Virus Illness and Serology in Mothers and Infants in the United States and South Africa. Nat. Med., provisional acceptance."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.4161\/hv.29635","article-title":"Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants","volume":"10","author":"Forbes","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_32","unstructured":"Centers for Disease Control and Prevention (CDC) (1997). Update: Respiratory syncytial virus activity\u2014United States, 1997\u20131998 season. MMWR Morb. Mortal. Wkly. Rep., 46, 1163\u20131165."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/infdis\/jiab505","article-title":"Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Co-Administered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine","volume":"225","author":"Peterson","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/infdis\/jiz390","article-title":"Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants","volume":"220","author":"Munoz","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/S0264-410X(03)00350-5","article-title":"Maternal immunization with Haemophilus influenzae type b vaccines in different populations","volume":"21","author":"Englund","year":"2003","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/infdis\/161.3.487","article-title":"Natural history of pertussis antibody in the infant and effect on vaccine response","volume":"161","author":"Decker","year":"1990","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ppul.21377","article-title":"Respiratory syncytial virus prevention and therapy: Past, present, and future","volume":"46","author":"Wright","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"ref_38","first-page":"210","article-title":"Respiratory syncytial virus bronchiolitis: Clinical aspects and epidemiology","volume":"51","author":"Boeck","year":"1996","journal-title":"Monaldi Arch. Chest Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1093\/infdis\/jiac155","article-title":"Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011\u20132019","volume":"226","author":"Suh","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/INF.0b013e31822e68e6","article-title":"Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997\u20132006","volume":"31","author":"Stockman","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2019-3611","article-title":"Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015\u20132016","volume":"146","author":"Rha","year":"2020","journal-title":"Pediatrics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jpids\/piz087","article-title":"Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014\u20132015","volume":"9","author":"Arriola","year":"2020","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Simoes, E.A., Anderson, E.J., Wu, X., and Ambrose, C.S. (2016). Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168882"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40121-017-0167-9","article-title":"Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States","volume":"6","author":"Parikh","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpeds.2008.07.053","article-title":"Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus","volume":"154","author":"Stensballe","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.inf.0000069796.72540.0a","article-title":"Maternal respiratory syncytial virus antibody titers: Season and children matter","volume":"22","author":"Gaboury","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/jmv.21026","article-title":"Respiratory syncytial virus infections in hospitalized infants: Association between viral load, virus subgroup, and disease severity","volume":"79","author":"Fodha","year":"2007","journal-title":"J. Med. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1016\/S1473-3099(18)30659-5","article-title":"Serocorrelates of protection against infant group B streptococcus disease","volume":"19","author":"Kampmann","year":"2019","journal-title":"Lancet Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1351\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:42:20Z","timestamp":1760114540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/12\/1351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["vaccines12121351"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12121351","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}